Advertisement

Archives of Osteoporosis

, 13:124 | Cite as

Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting

  • S. D. Berry
  • A. B. Dufour
  • T. G. Travison
  • H. Zhu
  • A. Yehoshua
  • R. Barron
  • C. Recknor
  • E. J. Samelson
Original Article
  • 106 Downloads

Abstract

Summary

In clinical practice, the frequency of patients achieving improved T-scores and the expected change in bone mineral density (BMD) according to osteoporosis drugs is unknown. We found that osteoporosis medications infrequently achieve improved femoral neck T-scores over 1.2 years. BMD increases were more often seen with IV bisphosphonates and denosumab.

Purpose

To determine the frequency of osteoporosis patients achieving improvement in T-scores and quantify the change in bone mineral density (BMD) over time according to osteoporosis medication use.

Methods

The study included all patients receiving clinical care at United Osteoporosis Centers, Gainesville, GA, 1995–2015, who had at least two measures of femoral neck BMD (N = 1232). We evaluated successive pairs of BMD tests to describe the distribution of transitions between T-score categories. Generalized estimating equations were used to estimate %BMD change between successive pairs of BMD tests according to osteoporosis medication, adjusted for age, sex, height, weight, baseline BMD, previous fracture, and follow-up time.

Results

Mean (±SD) age was 68 (±10) years, and 90% of patients were women. Mean baseline T-score was − 2.04 (± 0.85). In total, 1232 patients had 4918 pairs of successive BMD tests, with a mean 1.2 years (± 0.9) between assessments. Frequency of transition to an improved T-score category was 41% when prior T-score ≤ − 3.5, and 15% when prior T-score − 1.99 to − 1.50. Most individuals (69%) remained in the same T-score category. BMD increased 0.54% (95% CI 0.23–0.85%) with IV bisphosphonates and 1.23% (95% CI 0.56–1.90%) with denosumab, whereas no significant change was seen with oral bisphosphonates, teriparatide, or raloxifene.

Conclusions

Osteoporosis patients are unlikely to improve femoral neck T-scores over 1.2 years. Additional studies are needed to determine the optimal time to repeat BMD testing while receiving osteoporosis treatment and to determine whether fracture risk is reduced in patients who achieve target T-scores.

Keywords

Bone mineral density (BMD) T-score target Osteoporosis Medications 

Notes

Funding

This work was funded in part by an investigator initiated grant from Amgen. Investigators at Amgen did not have access to the data.

Supplementary material

11657_2018_528_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 14 kb)

References

  1. 1.
    What is Osteoporosis and What Causes it? 2017; https://www.nof.org/patients/what-is-osteoporosis/. Accessed July 21, 2017
  2. 2.
    Fischer S, Kapinos KA, Mulcahy A, Pinto L, Hayden O, Barron R (2017) Estimating the long-term functional burden of osteoporosis-related fractures. Osteoporos Int 28:2843–2851CrossRefGoogle Scholar
  3. 3.
    Schousboe JT (2017) Mortality after osteoporotic fractures; what proportion is caused by fracture and is preventable? A Commentary. J Bone Miner Res 32:1783–1788CrossRefGoogle Scholar
  4. 4.
    Weycker D, Li X, Barron R, Bornheimer R, Chandler D (2016) Hospitalizations for osteoporosis-related fractures: economic costs and clinical outcomes. Bone Rep 5:186–191CrossRefGoogle Scholar
  5. 5.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381CrossRefGoogle Scholar
  6. 6.
    Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract 22(Suppl 4):1–42CrossRefGoogle Scholar
  7. 7.
    Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of P (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818–839CrossRefGoogle Scholar
  8. 8.
    Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH (2014) Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int 25(9):2307–2311CrossRefGoogle Scholar
  9. 9.
    Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50(4):870–875CrossRefGoogle Scholar
  10. 10.
    Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan de Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32(1):3–10CrossRefGoogle Scholar
  11. 11.
    Michael Lewiecki E (2017) Osteoporosis: treat-to-target. Curr Osteoporos Rep 15(2):103–109CrossRefGoogle Scholar
  12. 12.
    Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, for the FLEX Research Group (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976–982CrossRefGoogle Scholar
  13. 13.
    Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85(1):231–236CrossRefGoogle Scholar
  14. 14.
    DM B EV, R E MB, McCulloch C, Cawthon PM et al (2015) Hip BMD by DXA can reliably estimate reduction in hip risk in osteoporosis trials: a meta-regression. J Bone Miner Res 30(S1):S49Google Scholar
  15. 15.
    MacIntyre NJ, Recknor CP, Grant SL, Recknor JC (2014) Scores on the safe functional motion test predict incident vertebral compression fracture. Osteoporos Int 25(2):543–550CrossRefGoogle Scholar
  16. 16.
    Recknor CP, Grant SL, Recknor JC, Macintyre NJ (2013) Scores on the safe functional motion test are associated with prevalent fractures and fall history. Physiother Can 65(1):75–83CrossRefGoogle Scholar
  17. 17.
    Johnell O, Kanis JA, Oden A, Johansson H, de Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194CrossRefGoogle Scholar
  18. 18.
    Genant HK, Li J, Wu CY, Shepherd JA (2000) Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 3(3):281–290CrossRefGoogle Scholar
  19. 19.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938CrossRefGoogle Scholar
  20. 20.
    Harris ST, Watts NB, Genant HK, McKeever C, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA 282(14):1344–1352CrossRefGoogle Scholar
  21. 21.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRefGoogle Scholar
  22. 22.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefGoogle Scholar
  23. 23.
    Ferrari S, Libanati C, Lin CJF, Adami S, Brown JP, Cosman F, Czerwinski E, de Gregório LH, Malouf J, Reginster JY, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM, Cummings S (2014) Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment. ACR/ARHP annual meeting. Available at: http://acrabstracts.org/abstract/percentage-of-women-achieving-non-osteoporotic-bmd-t-scores-at-the-spine-and-hip-over-8-years-of-denosumab-treatment/
  24. 24.
    Orford NR, Bailey M, Bellomo R, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Cooper DJ, Kotowicz MA (2017) The association of time and medications with changes in bone mineral density in the 2 years after critical illness. Crit Care 21(1):69CrossRefGoogle Scholar
  25. 25.
    Leslie WD, Brennan-Olsen SL, Morin SN, Lix LM (2016) Fracture prediction from repeat BMD measurements in clinical practice. Osteoporos Int 27(1):203–210CrossRefGoogle Scholar
  26. 26.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441CrossRefGoogle Scholar
  27. 27.
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture intervention trial research group. JAMA 283(10):1318–1321CrossRefGoogle Scholar
  28. 28.
    Leslie WD, Majumdar SR, Morin SN, Lix LM (2015) Why does rate of bone density loss not predict fracture risk? J Clin Endocrinol Metab 100(2):679–683CrossRefGoogle Scholar
  29. 29.
    Chapurlat RD, Palermo L, Ramsay P, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The fracture intervention trial. Osteoporos Int 16(7):842–848CrossRefGoogle Scholar
  30. 30.
    Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198–202CrossRefGoogle Scholar
  31. 31.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, for the Fracture Intervention Trial Long-Term Extension Research Group (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension. J Bone Miner Res 19(8):1259–1269CrossRefGoogle Scholar
  32. 32.
    Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23(3):1075–1082CrossRefGoogle Scholar
  33. 33.
    Michael Lewiecki E, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA (2018) Hip fracture trends in the United States, 2002 to 2015. Osteoporos Int 29(3):717–722CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • S. D. Berry
    • 1
    • 2
  • A. B. Dufour
    • 1
    • 2
  • T. G. Travison
    • 1
    • 2
  • H. Zhu
    • 1
  • A. Yehoshua
    • 3
  • R. Barron
    • 3
  • C. Recknor
    • 4
  • E. J. Samelson
    • 1
    • 2
  1. 1.Institute for Aging ResearchHebrew SeniorLifeBostonUSA
  2. 2.Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA
  3. 3.AmgenThousand OaksUSA
  4. 4.United Osteoporosis CentersGainesvilleUSA

Personalised recommendations